Related Experiment Video

Updated: Mar 4, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway

Minting Lin1, Hong Bi2, Yanyan Yan3

  • 1School of Pharmaceutical Sciences and The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, People's Republic of China.

Oncotarget
|April 21, 2017
PubMed

Insights

Parthenolide, a natural compound, effectively combats non-small cell lung cancer (NSCLC) by inhibiting B-Raf and the MAPK/Erk pathway. This study highlights its potential as a novel therapeutic agent for NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Products Chemistry

Background:

  • Non-small cell lung cancer (NSCLC) presents significant morbidity and mortality.
  • B-Raf mutations are key oncogenic drivers in NSCLC.
  • Parthenolide, derived from Tanacetum parthenium, is explored for its anti-cancer properties.

Purpose of the Study:

  • To investigate the anti-cancer effects of parthenolide on NSCLC cells.
  • To evaluate parthenolide's potential as a B-Raf inhibitor.
  • To elucidate the molecular mechanisms underlying parthenolide's action in NSCLC.

Main Methods:

  • Cytotoxicity assays (IC50 determination) were performed on NSCLC cells.
  • Apoptosis, proliferation, and invasion assays were conducted.
  • Western blotting and RNA interference were used to analyze molecular pathways, including B-Raf, MAPK/Erk, c-Myc, and STAT3 signaling.

Main Results:

  • Parthenolide demonstrated significant cytotoxicity against NSCLC cells (IC50: 6.07–15.38 μM).
  • Parthenolide induced apoptosis and suppressed proliferation and invasion.
  • Mechanistically, parthenolide inhibited B-Raf, suppressed the MAPK/Erk pathway, decreased c-Myc expression, and inhibited STAT3 activity.

Conclusions:

  • Parthenolide exhibits potent anti-NSCLC activity through B-Raf inhibition and MAPK/Erk pathway suppression.
  • Parthenolide's mechanism involves downregulation of c-Myc and STAT3 activity.
  • Parthenolide represents a promising therapeutic candidate for NSCLC treatment, acting as a B-Raf inhibitor.
Keywords:
B-RafMAPK/Erk pathwayc-Mycnon-small cell lung cancerparthenolide

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K